← Back to updates
Emerging treatmentsResults from peopleOne death and early observations; benefit unproven

Interim human results from a Phase 1 study with one treatment group and no comparison group

Zola-cel: one death and early observations in a Phase 1 CAR-T study in 66 people with MS

Published by MyelinWatch:

What happened

On 23 October 2026, Bristol Myers Squibb reported interim results from the Phase 1 Breakfree-2 study of zola-cel, an experimental CD19-directed CAR T-cell therapy made from a person's own cells and given as a single infusion. One person with highly active relapsing multiple sclerosis (MS) died of septic pneumonia 44 days after the infusion. The death happened after the data cutoff. This person had late-onset motor symptoms, described as non-ICANS, that did not resolve with corticosteroids and intravenous immunoglobulin, received high-dose cyclophosphamide, developed septic pneumonia and died the following day. The study has no comparison group. It included 66 people: 30 with highly active relapsing MS and 36 with progressive MS. Cytokine release syndrome occurred in 28/66 and the neurotoxicity syndrome ICANS in 5/66, including one Grade 4 event that resolved within four days. Among people who received the main dose and had at least 26 weeks of follow-up, 22 of 24 with progressive MS were reported as stable or improved on disability and all 24 had no new MRI activity. In highly active relapsing MS, 6 of 7 evaluable people had no evidence of disease activity.

What this means for people with MS

Without a comparison group, these observations cannot show that zola-cel caused the stability seen, and they cannot show that it slows disability. Follow-up is short: among the 60 people who received the main dose, the company reports nine with more than 12 months. The reported cause of death was septic pneumonia; how zola-cel and the treatment that followed contributed remains unresolved. A company spokesperson told Reuters that other complications and heavy prior treatment confound finding the root cause, as quoted by Pharmaceutical Executive. The presenter, Jeffrey Cohen, said the death was presumed to be in some way related to the CAR-T therapy, as reported by Healio. Pharmaceutical Executive also reported that the company paused zola-cel studies in September 2026 and aims to resume enrolment in early 2027; the company release does not mention this. Zola-cel is experimental and is not an available MS treatment.

What kind of evidence exists?
Bristol Myers Squibb announcement of interim conference results; single-arm Phase 1 study, not peer reviewed
How reliable is this source?
Primary company announcement of interim conference results, not peer-reviewed; the conference abstract was not read. Quoted statements on the cause of death come from specialist news reports. Healio reports 57 participants, while the company release reports 66; the figure here follows the company release.
Source: Bristol Myers Squibb — official company announcement ↗Source: ClinicalTrials.gov — Breakfree-2, NCT06220201 ↗ Source: Healio — report of the presentation, 2 November 2026 ↗ Source: Pharmaceutical Executive — report on the death and the study pause, 26 October 2026 ↗
Research event/source date
Published by MyelinWatch
Last substantive MyelinWatch update

Related substantive developments

Research event/source date:
Emerging treatmentsRegistered study in peopleRegistered study plan; no results

Registered Phase 1/2 study; not yet accepting participants; start estimated for January 2027

UKT-CART19.1: a CAR-T study in autoimmune diseases including MS was registered in Tübingen

Organisation: University Hospital Tübingen · Germany

ClinicalTrials.gov first posted NCT07932262 on 12 November 2026. The sponsor is University Hospital Tübingen in Germany. This is a single-centre, open-label Phase 1/2 study with one treatment group. It tests UKT-CART19.1, CAR-T cells made from the person's own T cells and aimed at CD19, a marker on B cells. The same treatment, given as one infusion, is tested in adults aged 18 to 80 with seven relapsed or treatment-resistant autoimmune diseases, one of which is multiple sclerosis (MS). People with MS must have had recent disease activity (a relapse, worsening or new MRI activity in the previous 24 months) and must not have responded to at least two high-potency MS medicines (category 3 in the German guideline). The registry estimates 36 participants in total for all diseases and does not say how many will have MS. The main outcome is safety over 6 months. The EU clinical trials register (CTIS) shows authorisation in Germany on 14 August 2026. ClinicalTrials.gov lists the study as not yet accepting participants, with an estimated start in January 2027.

Published by MyelinWatch:

What this means for people with MS

Registration and authorisation describe a study plan. They do not show that anyone has been enrolled or treated, or that UKT-CART19.1 works or is safe in MS, and no results are posted. The estimated start differs between the two records (recruitment from 1 July 2026 in CTIS, January 2027 on ClinicalTrials.gov), and neither shows that recruitment has begun. The study has one centre, in Tübingen, and neither record lists a site in Greece, so it is not an established route to treatment for people in Greece. Eligibility is decided by the study team, whose contacts are in the registry. Participants are to be followed for up to 15 years, as required for gene-therapy studies.

Research event/source date:
Emerging treatments + myelin repairRegistered study in peopleFirst participant dosed; no results posted

Combined early Phase 1/2a study in people; no results posted

PRO-1562: Progentos reports first participant dosed in an early study of a possible myelin-repair drug

Organisation: Progentos Therapeutics · United States

On 3 November 2026, Progentos Therapeutics announced that the first participant has been dosed in its Phase 1/2a study of PRO-1562 (NCT07826689), an experimental oral small molecule designed to repair myelin in multiple sclerosis (MS). The company did not give the dosing date or say in which part of the study this happened. It describes the Phase 1 part as placebo-controlled single rising doses in healthy adults at one site in Australia, so the announcement does not show whether that participant received PRO-1562 or placebo. The later Phase 2a part plans six months of once-monthly doses or placebo in adults with relapsing MS and chronic optic neuropathy. The company says that the drug promoted myelin repair in laboratory and animal studies; it reports no human results. The ClinicalTrials.gov record, last updated on 29 September 2026 and checked on 6 November, still shows the study as accepting participants, an estimated October 2026 start and no posted results.

Published by MyelinWatch:

What this means for people with MS

According to the company, this study has started dosing. That does not show that PRO-1562 is safe, that it repairs myelin in people or that it helps people with MS. Laboratory and animal results may not apply to people. The announcement does not establish that the MS part has opened. PRO-1562 is an experimental drug, not an available treatment. The registry lists one site, in Adelaide, Australia, and none in Greece. No established approved treatment in clinical practice has been proven to reliably restore myelin in MS.

Research event/source date:
Emerging treatmentsRegistered study in peopleStudy authorised in Greece; not a result

Phase 3 extension study authorised in Greece; recruitment not yet started

Frexalimab: Greece authorises the long-term Phase 3 extension study

Organisation: Sanofi · France

The EU Clinical Trials Information System (CTIS) shows that Greece authorised Sanofi's Phase 3 extension study LTS18002 (2026-525688-41-00) on 2 November 2026. Denmark, Portugal and Poland authorised it on the same day, after Belgium (30 October 2026) and Austria (1 November 2026); all six countries are listed as authorised with recruitment pending. The record plans 17 participants in Greece and lists four Greek hospitals: AHEPA University General Hospital of Thessaloniki, the University General Hospital of Ioannina, the General University Hospital of Larissa and the 401 General Military Hospital of Athens. The study will look at the long-term safety and tolerability of frexalimab, an experimental antibody, in people with multiple sclerosis (MS). It is open only to people who complete earlier frexalimab studies on the study drug, such as the Phase 3 studies FREXALT and FREVIVA. The estimated EU recruitment start is 15 February 2027.

Published by MyelinWatch:

What this means for people with MS

Authorisation means the study may proceed in Greece; it does not mean that it has started at any Greek hospital, that anyone has received treatment in it, or that frexalimab works. No Phase 3 results are available yet. People who are not already in a frexalimab study cannot join this extension, so it is not a way for other people with MS in Greece to receive frexalimab. Frexalimab is not an available treatment in Greece.